Virios Therapeutics, Inc. is a clinical‐stage biopharmaceutical company dedicated to developing novel neuropsychiatric treatments that leverage insights from psychedelic research. The company’s research and development efforts focus on proprietary small molecules designed to modulate key neurological pathways implicated in conditions such as post‐traumatic stress disorder (PTSD), depression and anxiety. By optimizing molecular structures related to naturally occurring psychoactive compounds, Virios seeks to create therapies that deliver targeted clinical benefits while minimizing undesirable hallucinogenic effects.
The company’s pipeline includes several lead candidates in various stages of preclinical and early clinical development. These programs are supported by a growing chemistry library and strategic collaborations with academic centers of excellence. Virios’ team employs streamlined synthesis and translational pharmacology platforms to accelerate the identification of molecules with favorable safety, pharmacokinetic and pharmacodynamic profiles. In parallel, the company is advancing manufacturing processes in compliance with Good Manufacturing Practice (GMP) standards to ensure scalability for eventual commercial supply.
Founded in 2020, Virios Therapeutics emerged from a reverse merger that combined the assets of a Canadian biotech group with a U.S. specialty pharmaceutical platform. Headquartered in New York with research operations in Toronto, the company serves markets across North America and Europe. Over a short period, Virios has established partnerships to access external expertise in neuroimaging, clinical trial design and regulatory affairs, laying the groundwork for global development programs in both academic and commercial settings.
The leadership team at Virios brings together seasoned executives and scientific experts from the pharmaceutical and biotechnology sectors. Its board of directors and advisory council comprise neuroscientists, psychiatrists and drug development veterans who have guided multiple molecules from discovery through regulatory approval. With a mission to address significant unmet needs in mental health, Virios continues to build its capabilities in clinical operations, regulatory strategy and strategic alliances to support the advancement of its innovative therapeutic candidates.
AI Generated. May Contain Errors.
Free VIRI Stock Alerts